Ramírez-Hobak L, Moreno-Coutiño G, Arenas-Guzmán R, Gorzelewski A, Fernández-Martínez R

Language: Spanish
References: 14
Page: 458-461
PDF size: 81.12 Kb.

ABSTRACT

Introduction: Erythrasma is caused by Corinebacterium minutissimum producing a porphyrin that with Wood’s light emits a coral-red fluorescence. It is the most common bacterial infection of the feet. Ozonated olive oil decreases the cytoplasm and damages bacterial proteins and lipids. Treatment is with oral erythromycin and there is no consensus regarding the topical therapy of choice. The aim of this paper is to evaluate the therapeutic efficacy of ozonated olive oil in a pilot trial for Erythrasma.
Methods: Experimental, open, observational, descriptive, longitudinal clinical trial at the section of Mycology, of the General Hospital “Dr. Manuel Gea González”. Patients: 10 individuals with interdigital feet Erythrasma. Intervention: ozonated olive oil every 12 hours for 10 days was given.
Results: All patients had disappearance of coral-red fl uorescence, erythema, fi ssures, pruritus, and maceration; two patients persisted with scaling. A cure was obtained in 100 % of patients, similar to oral erythromycin response.
Conclusions: Ozonated olive oil is a good topical treatment option for interdigital Erythrasma avoiding oral medications. Larger studies are required.

REFERENCES

1. Chodkiewicz HM,Cohen PR. Erythrasma: successful treatment after single-dose-clarithromycin. Int J Dermatol 2013;52(4):516-518.

2. Blaise G, Nikkels AF, Hermanns-Lê T, Nikkels-Tassoudji N, Piérard GE. Corynebacterium-associated skin infections. Int J Dermatol 2008;47(9):884-890.

3. Morales-Trujillo ML, Arenas R, Arroyo S. [Interdigital erythrasma: clinical, epidemiologic, and microbiologic fi ndings]. Actas Dermosifi liogr 2008;99(6):469-473.

4. Holdiness M. Managment of cutaneous eritrasma. Drugs 2002;62(8):1131-1141.

5. Avci Oktay. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat 2013;24:70-74.

6. Bocci V. Scientifi c and medical aspects of ozone therapy. State of the art. Arch Med Res 2006;37(4): 425-435.

7. Falcón-Lincheta L, Menéndez-Cepero S, Daniel- Simón R, Garballo-Otaño E, Moya-Duque S, Abreu- García M. Aceite ozonizado en Dermatología. Experiencia de 9 años. CENIC Ciencias Biológicas 1998; 29(3):192-195.

8. Valacchi G, Fortino V, Bocci V. The dual action of ozone on the skin, topical review. Br J Dermatol 2005; 153(6):1096-1100.

9. Bocci VA. Tropospheric ozone toxicity vs. usefulness of ozone therapy. Arch Med Res 2007;38(2):265-267.

10. Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated oils in skin diseases: a review. Mediators Infl amm 2010;2010:1-9.

11. Lezcano I, Núñez N, Gutiérrez M, Molerio J, Regüeiferos MG, Díaz W. Actividad in vitro del aceite de girasol ozonizado (OLEOZON) frente a diferentes especies bacterianas. CIENIC Ciencias biológicas 1996;27(1-3):46-49.

12. Curtiellas V, Gómez M, Ledea O, Fernández I, Sánchez E. Actividad antimicrobiana del OLEOZON sobre Staphylococcus aureus y Pseudomonas aeruginosa. CENIC Ciencias Biológicas 2005;36. Número especial.

13. Curtiellas V, Ledea O, Rodríguez S, Ancheta O, Echevarría M, Sánchez E et al. El OLEOZON sobre la viabilidad, la permeabilidad celular y la ultraestructura de Staphylococcus aureus. CENIC Ciencias Biológicas 2008;39(2):128-131.

14. Menéndez S, Fernández M, Amoroto M, Uranga R, Acuña P, Benítez JE et al. Efi cacia y seguridad del OLEOZON tópico en el tratamiento de pacientes con impétigo. Rev Panam Infectol 2007;9(2):23-29.